Comparative Pharmacology
Head-to-head clinical analysis: AGGRASTAT versus KENGREAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRASTAT versus KENGREAL.
AGGRASTAT vs KENGREAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirofiban is a reversible antagonist of glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by blocking fibrinogen binding.
Cangrelor is a reversible, direct-acting P2Y12 platelet receptor antagonist that inhibits ADP-mediated platelet activation and aggregation.
A loading dose of 25 mcg/kg administered intravenously over 3 minutes, followed by a maintenance infusion of 0.15 mcg/kg/min for up to 18 hours. For patients with severe renal impairment (GFR <30 mL/min), the maintenance infusion rate is reduced to 0.075 mcg/kg/min.
10 mcg/kg intravenous bolus over 1-2 minutes, followed by 0.1 mcg/kg/min continuous intravenous infusion for 2-4 hours.
None Documented
None Documented
Terminal half-life: ~2 hours; clinical context: requires continuous IV infusion for sustained antiplatelet effect
Terminal elimination half-life is approximately 3–6 minutes (mean 3.3 minutes), allowing rapid recovery of platelet function within 60 minutes of infusion cessation.
Renal: 65% unchanged drug; biliary/fecal: minimal (<5%)
Cangrelor is metabolized via rapid dephosphorylation to its major metabolite, a nucleoside, which is further degraded; approximately 58% of the dose is excreted in urine as unchanged cangrelor and metabolites, with <35% in feces.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent